Gyre Therapeutics (GYRE) Cost of Revenue (2020 - 2026)

Gyre Therapeutics (GYRE) has 7 years of Cost of Revenue data on file, last reported at $14.1 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $14.1 million, up 1481.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.5 million (up 179.16% YoY), and the FY2025 annual result was $65.2 million, up 13.33% from the prior year.
• Cost of Revenue slipped to $14.1 million in Q1 2026 per GYRE's latest filing, from $61.5 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $61.5 million in Q4 2025 and troughed at $798000.0 in Q1 2022.
• A 5-year average of $13.5 million and a median of $1.6 million in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue jumped 2077.67% in 2022, then slumped 97.66% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $53.4 million in 2022, then sank by 97.66% to $1.2 million in 2023, then surged by 1248.48% to $16.9 million in 2024, then soared by 264.89% to $61.5 million in 2025, then sank by 77.02% to $14.1 million in 2026.
• Business Quant data shows GYRE's Cost of Revenue at $14.1 million in Q1 2026, $61.5 million in Q4 2025, and $1.6 million in Q3 2025.